Advisory Boards

The TB Alliance established a Scientific Advisory Committee to provide invaluable scientific guidance.

The Scientific Advisory Committee provides technical expertise on drug research, development, manufacturing, and distribution, as well as other medical and scientific issues. It consists of fifteen experts from a wide range of relevant disciplines.

Stakeholder institutions advise, guide, and support the efforts of TB Alliance.

The TB Alliance Stakeholders Association (SHA) is an advisory committee which provides advice and support to on activities related to the research & development of anti-tuberculosis medicines and regimens; access to new TB products, the fulfilment of TBAlliance’s AAA Mandate â€“ that all new products are adopted, available and affordable; dissemination and sharing of relevant information globally; and to participate in fundraising and advocacy efforts.

The SHA President is elected by active SHA members and serves as a voting ex officio member of the TB Alliance Board of Directors.

Mitchell Warren
Stakeholders Association President
Executive DirectorAVAC

Our Access Advisory Committee assists in our efforts to lower barriers to access to new TB cures.

The Access Advisory Committee (AAC) assists, supports, and advises the TB Alliance on strategies and approaches to achieve adoption, availability, and affordability of new treatment regimens. The group provides ideas, advice, and contacts offering critical thinking on ways to reduce barriers to access.

Alena Skrahina

The Republican Research and Practical Centre for Pulmonology and TB, Belarus

Matteo Zignol

Research for TB Elimination, World Health Organization (WHO)